Source: Pharmacy Times articles
Incretin-based therapies, including GLP-1 and dual GLP-1/GIP receptor agonists, are transforming the management of type 2 diabetes, obesity, and cardiovascular risk.
Read More
by MM360 Staff | Jun 1, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
Incretin-based therapies, including GLP-1 and dual GLP-1/GIP receptor agonists, are transforming the management of type 2 diabetes, obesity, and cardiovascular risk.
Read More